Sirolimus monotherapy for Erdheim–Chester disease.

Autor:	van Bommel, Eric F. H., van der Zijden, Mark A., Smak Gregoor, Peter J. H., Hendriksz, Tadek R., Ho-Han, Shiuw H., Westenend, Pieter J.
Předmět:	RAPAMYCIN DIFFERENTIAL diagnosis TREATMENT effectiveness NON-langerhans-cell histiocytosis THERAPEUTICS
Zdroj:	Acta Oncologica; Jun2019, Vol. 58 Issue 6, p901-905, 5p, 1 Color Photograph, 2 Charts
Abstrakt:	The article present a case report of 75-year-old man, 70-year-old male and 61-year-old man with Erdheim–Chester Disease (ECD), a rare, non-Langerhans histiocytosis, characterized by the accumulation of foamy macrophages, chronic inflammation, fibrosis and organ failure. It mentions Interferon alfa (IFNa) is the most commonly prescribed empiric treatment for ECD patients; and also mentions that two patients were treatmentnaive, one patient had received prior treatment with prednisone (PDN).
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.